Building the foundation for modern medicine
Today, we're introducing Forus (formerly Tandem) and announcing that we've raised $160M from Thrive Capital, General Catalyst, Accel, Bain Capital Ventures, Redpoint, BoxGroup, and Pear VC.
Forus accelerates medicine for the people who need it, prescribe it, and create it. We are building the AI-powered network that connects doctors, pharmacies, payers, and biopharma to bring new science to patients.
Science should be the only limit to medicine. Today it isn't.
Scientific progress in medicine is accelerating, but getting breakthroughs to patients remains slow and unreliable. Bringing a new drug to market takes 10 to 15 years and costs $2.6 billion on average. Even after FDA approval, too many eligible patients never receive treatment — caught in a system that wasn't built for the complexity of modern medicine. Most promising drugs never make it to market, and those that do reach only a fraction of the patients who could benefit.
Drug discovery is moving faster, but the system that turns it into real-world treatment isn't. We're building the infrastructure to change that.
Building an AI-powered network to accelerate medicine
Forus is embedded into physician workflows, automating all steps between a clinical decision and a patient starting treatment: insurance authorization, financial assistance, and fulfillment routing. We do this for every drug, payer, and pharmacy in the country — free for doctors and patients. By abstracting away complexity, Forus gives doctors the confidence to prescribe the most effective treatments, and patients who used to wait weeks or months are starting treatment in days.
And because Forus plays an unprecedented role in moving prescriptions through the system, our network provides unique insight into where providers get stuck, where patients drop off, and how medicines perform across populations. That perspective helps life sciences companies design better research, launch new therapies more effectively, and invest in harder-to-treat conditions. Five of the top 10 global biopharma companies are already working with Forus.
Forus is used by thousands of medical practices and health systems in all 50 states and is expanding rapidly across specialties. Provider adoption grew 10x year-over-year for the last two years, driven by word of mouth. We already support patients in nearly 80% of U.S. zip codes, including many with complex conditions who are now, for the first time, on treatment that could change the course of their disease.
What we’re hearing from the field
Getting medications approved has always been a battle of forms, faxes, and phone calls that consumed our team's day. We had patients who spent months trying to get approved and couldn't. With Forus, approvals that used to take months are happening in 2-3 days. The time our team gets back goes straight into patient care.
FAAD / Medical Director, AQUA Dermatology
For years, I've had patients who couldn't get the medications they needed in a timely manner — or at a price they could afford. Since we've started working with Forus, our physicians can prescribe the most effective treatment with the confidence that patients will start and stay on therapy as recommended.
FACP, FACG / Chairman, OneGI
AI is transforming every industry, and medicine is no exception. In rheumatology, where patients can wait weeks for complex therapies, the technology can't come fast enough. Forus puts AI at the center of the access process, and what used to take my team an entire day is now handled automatically. Our patients feel the difference: they get on therapy faster, with far fewer of the calls, denials, and surprises that made a difficult diagnosis even harder to live with.
Managing Partner, Sarasota Arthritis Centers
The path ahead
We are investing across three priorities:
Grow the network. Our goal is to be in every doctor's office in the country. We've proven the model — now it's time to scale across specialties and sites of care, reaching more physicians and more patients.
Deepen the platform. Every prescription touches insurance systems, pharmacy networks, clinical records, and affordability programs — each with its own rules and failure modes. We're building AI that navigates all of it: agents that handle complex multi-step processes autonomously, and clinical models that get better with every prescription we process.
Build the team. There's an opportunity to unlock an order of magnitude more medicine for society. We have an exceptional team of about 100 engineers and operators in New York, and we're looking for more high-horsepower, high-throughput individuals whose ambition matches that goal.
Our number one priority is scaling to meet demand. We move fast and need to move faster. If we succeed, science will be the only limit to medicine. If that excites you, get in touch.
